Eli Lilly and Company (LLY)vsRoivant Sciences Ltd (ROIV)
LLY
Eli Lilly and Company
$948.45
-2.72%
HEALTHCARE · Cap: $869.41B
ROIV
Roivant Sciences Ltd
$28.56
+0.99%
HEALTHCARE · Cap: $20.24B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 542717% more annual revenue ($72.25B vs $13.31M). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ROIV
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 108 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 27.2x book value
0.0% margin — thin
ROE of -19.1% — below average capital efficiency
Revenue declined 77.8%
Earnings declined 96.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : ROIV
The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ROIV
The primary concerns for ROIV are Profit Margin, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while ROIV is a value play — different risk/reward profiles.
ROIV carries more volatility with a beta of 1.14 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 24/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Roivant Sciences Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Roivant Sciences Ltd (ROIV) is an innovative biopharmaceutical company dedicated to revolutionizing drug development and commercialization through its unique business model and proprietary technologies. The company boasts a robust and diverse pipeline targeting significant unmet medical needs across neurology, immunology, and rare diseases, aiming to expedite the drug development process while minimizing costs. Roivant's experienced leadership team and strategic collaborations position it well to transform the healthcare landscape, offering compelling value propositions for investors and improving patient outcomes.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?